2315.HK

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.

Metric	Historical average			My assumptions
Metric	1 year	5 years	10 years	Low	Mid	High
ROIC %	21.5%			—	—	—
Rev. Growth %	40.6%	40.3%		Rev. Growth Low%	Rev. Growth Mid%	Rev. Growth High%
Profit Margin %	12.6%	-60.8%		Profit Margin Low%	Profit Margin Mid%	Profit Margin High%
Free Cash Flow Margin %	20.5%	-50.2%		Free Cash Flow Margin Low%	Free Cash Flow Margin Mid%	Free Cash Flow Margin High%
Exit P/E	—	—	—	Exit P/E Low×	Exit P/E Mid×	Exit P/E High×
Exit P/FCF	—	—	—	Exit P/FCF Low×	Exit P/FCF Mid×	Exit P/FCF High×
Desired Annual Return %	—	—	—	Desired Annual Return Low%	Desired Annual Return Mid%	Desired Annual Return High%

Low

Multiple of earnings (P/E): —
IRR at today’s price (P/E): —
Fair buy price today (P/E): —
Multiple of cash flow (P/FCF): —
IRR at today’s price (P/FCF): —
Fair buy price today (P/FCF): —

At today's price, your expected annual return is — on the P/E track.

Mid

Multiple of earnings (P/E): —
IRR at today’s price (P/E): —
Fair buy price today (P/E): —
Multiple of cash flow (P/FCF): —
IRR at today’s price (P/FCF): —
Fair buy price today (P/FCF): —

At today's price, your expected annual return is — on the P/E track.

High

Multiple of earnings (P/E): —
IRR at today’s price (P/E): —
Fair buy price today (P/E): —
Multiple of cash flow (P/FCF): —
IRR at today’s price (P/FCF): —
Fair buy price today (P/FCF): —

At today's price, your expected annual return is — on the P/E track.

Current price: —Annual dividends: $0.00/shareNet cash / debt per share: $2.45FMP DCF cross-reference: -$171.38

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$2.0B	+48.5%	$0.80	$0.72–$0.89	—	3
2027	$2.7B	+34.9%	$1.28	$1.17–$1.40	—	3
2028	$3.7B	+36.7%	$1.91	$1.89–$1.93	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 1 of the last 5 reported quarters

Reported	Est. EPS	Actual	Surprise
2025-03-26	$0.01	$0.23	+2099.2%
2024-08-28	$-0.13	$-0.14	-8.3%
2024-03-27	$-0.48	$-0.53	-9.1%
2023-08-28	$-0.44	$-0.52	-17.1%
2023-03-27	$-0.55	$-0.97	-75.5%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
2315.HKBiocytogen Pharmaceuticals (Beijing) Co., Ltd.	$57.00	-4.12%	$23.1B	—
1672.HKAscletis Pharma Inc.	$8.94	-0.67%	$9.4B	—
1858.HKBeijing Chunlizhengda Medical Instruments Co., Ltd.	$7.72	-1.47%	$4.6B	—
2142.HKHBM Holdings Limited	$12.73	-4.86%	$10.7B	—
2157.HKLepu Biopharma Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.

biocytogen.com.cn

Employees: 1,443
IPO / List date: Sep 1, 2022

Held by traders on TradeandTell

No one on the platform currently holds 2315.HK.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 2315.HK as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 2315.HK yet.